AI boom makes inroads in GI: AI may improve diagnosis, experts still urge caution healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
DENVER — Providers should consider de-escalating combination therapy with immunomodulators to monotherapy after 1 year in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress.
“We know that combination therapy is one of our most, if not the most, effective therapies: not the combination of biologics, but the combination of the
Chronic inflammation of the digestive tract is referred to as inflammatory bowel disease (IBD), of which Crohn's disease is a type. The small intestine
Two of the most important goals in the treatment of patients with inflammatory bowel disease are to improve patient quality of life and increases the odds of remission.